EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection

Lukas M Carter, Sophie Poty iD, Sai Kiran Sharma iD, Jason S Lewis iD

Journal of Labelled Compounds and Radiopharmaceuticals · 2018-07 · 61 (9) · 611-635

DOI: 10.1002/jlcr.3612 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 30.03.2018. Verfasst von Lukas M Carter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally exquisitely specific and selective vectors, enabling recognition of individual cancer‐associated molecular phenotypes against a complex and dynamic biomolecular background. Complementary alignment of these advantages with unique properties of radionuclides is a defining paradigm in both radioimmunoimaging and radioimmunotherapy, which remain some of the most adept and promising tools for cancer diagnosis and treatment. This review discusses how translational potency can be maximized through rational selection of antibody‐nuclide couples for radioimmunoimaging/therapy in preclinical models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAntibodiesHumansNeoplasmsRadioimmunotherapyRadiopharmaceuticalsTissue Distribution

Stichwörter der Autor:innen

animal modelantibodyimagingradionuclidetherapy

Substanzen

AntibodiesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, New York, USA.
  • Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Sophie Poty, Sai Kiran Sharma, Jason S Lewis

Förderung

  • NIBIB NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Carter, L. M., Poty, S., Sharma, S. K., & Lewis, J. S. (2018). Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals, 61(9), 611-635. https://doi.org/10.1002/jlcr.3612

Vancouver

Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals. 2018;61(9):611-635. doi:10.1002/jlcr.3612

BibTeX
@article{Carter2018,
  author = {Carter, Lukas M and Poty, Sophie and Sharma, Sai Kiran and Lewis, Jason S},
  title = {Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2018},
  volume = {61},
  number = {9},
  pages = {611--635},
  doi = {10.1002/jlcr.3612}
}
Kostenlos starten →